FS.COM
19.6.2020 10:02:08 CEST | Business Wire | Press release
FS.COM , a high-speed communication product and solution provider for data centers, enterprises, and telecom networks, collaborated with US Conec, a leader in providing passive components for high density optical interconnects, to supply MTP® brand cable assembly products for high density data center applications.
With the ever-growing demands on high speed networks, MTP® cabling systems are required to provide more connections in limited space applications. “Each FS MTP® cable uses US Conec's MTP® connectors to ensure stable and highly effective interconnections of MTP® cabling infrastructure in data center environments. US Conec's MTP® connectors are recognized as the industry leading high density cabling solution for low insertion loss, excellent optical performance and space saving advantages,” said Daniel Xiang, CEO of FS.COM. “In addition to MTP® cabling products, FS.COM has introduced ancillary products from the MTP® family including MTP® cleaners, MTP® adapters and field tools for MTP® PRO connector.”
MTP® cleaners
- Clean ferrules of MT based connectors with simple push for cabling assemblies and field installation
MTP® adapters
- Compatible with all US Conec MTP® brand connectors from 4 to 72 fibers for coupling and debris protection
Field tools for MTP® PRO connector
- Simple change of MTP® PRO cable polarity and pins in less than a minute
“We are excited to partner with FS.COM to deliver optical technology and connectivity solutions that will drive the next generation of communications infrastructure worldwide,” states Joe Graham, President of US Conec. “FS.COM has demonstrated strong market access and we feel that together we can deliver superior value to our collective customer base.”
MTP® is a registered trademark of US Conec Ltd.
About US Conec
US Conec is a global leader in the design and development of high-density optical interconnects. With nearly 30 years of innovative experience, the company provides industry leading components for data center and enterprise structured cabling, public networks, on-board optical interconnects, industrial and military markets worldwide. Key product developments include single-mode and multimode MT-style and custom multi-fiber ferrules, MTP® brand MPO connectors, MXC® connectors, PRIZM® LightTurn® and PRIZM® MT lensed ferrule technology, ELiMENT™ single fiber connector solutions, IBC™ brand fiber optic cleaning solutions, termination equipment for multi-fiber interconnects, and high precision optical packaging components. US Conec is headquartered in Hickory, North Carolina, and is an equity venture of three leading communication technology companies—Corning Optical Communications, Fujikura, and NTT-AT.
About FS.COM
FS.COM is a high-speed communication product and solution provider for connecting and securing global data center, enterprise, and telecom networks. FS.COM is dedicated to fulfilling product systems and tailoring project solutions for IT professionals with immediate services by developing its talents, labs and local service center. Through continuous technology innovation and brand partnership, FS products and solutions have served more than 300,000+ customers in over 200 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005075/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom